The company’s lead compound ricolinostat is an oral, selective inhibitor of the microtubule-modifying enzyme histone deacetylase 6 (HDAC6). With first-in-class potential, ricolinostat is ...

Scientists from the University of Sharjah say they have good news for breast cancer patients, particularly those afflicted ...

Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative ...

Lytic induction therapy has been developed to selectively kill EBV-positive cancer cells by triggering viral reactivation ...

Over four hundred people, 80% of them being children under 14 years old, will be diagnosed with B-cell Acute Lymphoblastic ...

Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative ...

The restructuring is aimed at freeing up resources so the firm can advance its EBV-positive peripheral T-cell lymphoma drug toward the market.

“You should have the exact mutation of your patient, and then you can look and see what they're eligible for,” she said.

- Reprioritized resources to reduce costs and enhance focus on Nana-val’s development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to report data from ...

Dr. Booij’s research programme has a special focus on biopsychosocial pathways to eating disorders. She conducts her research in both clinical populations and longitudinal community-based samples and ...

12,077,515, titled “Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease.” This patent was officially issued on September 3, 2024, further strengthening Shuttle Pharma ...